Comparison · NCT04146896-c69710aa
NYX-2925 vs Placebo: Number of Subjects Achieving ≥30% Pain Reduction
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. NYX-2925 vs Placebo: Number of Subjects Achieving ≥30% Pain Reduction. Trial comparisons, record NCT04146896-c69710aa. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04146896-c69710aa
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.451 | 0.363 | 0.543 | wilson | |
| Risk in group 2 | 0.464 | 0.375 | 0.556 | wilson | |
| Risk difference, group 1 minus group 2 | -0.013 | -0.141 | 0.115 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.972 | 0.731 | 1.29 | log | |
| Odds ratio, group 1 over group 2 | 0.949 | 0.562 | 1.6 | log | |
| Number needed to treat, for one fewer participant with the outcome on NYX-2925 than on Placebo | 77.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | NYX-2925 | NYX-2925 50 mg QD~NYX-2925 50 mg: NYX-2925 administered orally | 51 | 113 | OG000 |
| Group 2 | Placebo | Placebo QD~Placebo: Placebo administered orally | 52 | 112 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects Achieving ≥30% Pain Reduction
- Description
- Number of subjects achieving ≥30% pain reduction from baseline in the weekly mean NRS average pain intensity related to DPN
- Time frame
- Week 12
- Population
- Population Description: Modified Intent to Treat Population includes all subjects who received at least one dose of study drug with at least one post-baseline assessment of the pain intensity NRS
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)
- NCT number
- NCT04146896
- Phases
- PHASE2
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- NYX-2925 50 mg, Placebo
- Lead sponsor
- Aptinyx
- Results first posted
- 2023-04-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04146896?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04146896-c69710aa